Crizotinib Interm 7654

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 610232

CAS#: 877397-65-4

Description: Crizotinib Interm 7654 is an important intermediate for the synthesis of pharmaceutical compounds.


Chemical Structure

img
Crizotinib Interm 7654
CAS# 877397-65-4

Theoretical Analysis

MedKoo Cat#: 610232
Name: Crizotinib Interm 7654
CAS#: 877397-65-4
Chemical Formula: C8H7Cl2FO
Exact Mass: 207.9858
Molecular Weight: 209.04
Elemental Analysis: C, 45.96; H, 3.38; Cl, 33.92; F, 9.09; O, 7.65

Size Price Shipping out time Quantity
1kg USD 3650 2 Weeks
2kg USD 5650 2 Weeks
Inquire bulk and customized quantity

Pricing updated 2021-02-27. Prices are subject to change without notice.

Crizotinib Interm 7654, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Synonym: Crizotinib Interm 7654; Crizotinib Intermediate; (S)-1-(2,6-Dichloro-3- fluorophenyl)ethanol; BenzeneMethanol,2,6-dichloro-3-fluoro-a-Methyl-, (aS)-;(1S)-1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol;(S)-1-(2,6 -dichloro-4-fluorophenyl)ethanol

IUPAC/Chemical Name: (1S)-1-(2,6-dichloro-3-fluorophenyl)ethanol

InChi Key: JAOYKRSASYNDGH-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H7Cl2FO/c1-4(12)7-5(9)2-3-6(11)8(7)10/h2-4,12H,1H3

SMILES Code: CC(C1=C(C=CC(=C1Cl)F)Cl)O

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code:
2934.99.9001

Handling Instructions:

Preparing Stock Solutions

The following data is based on the product molecular weight 209.04 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Bresler SC, Weiser DA, Huwe PJ, Park JH, Krytska K, Ryles H, Laudenslager M, Rappaport EF, Wood AC, McGrady PW, Hogarty MD, London WB, Radhakrishnan R, Lemmon MA, Mossé YP. ALK mutations confer differential oncogenic activation and sensitivity to ALK inhibition therapy in neuroblastoma. Cancer Cell. 2014 Nov 10;26(5):682-94. doi: 10.1016/j.ccell.2014.09.019. Epub 2014 Nov 10. PubMed PMID: 25517749; PubMed Central PMCID: PMC4269829.
 
2: Clegg IM, Daly AM, Donnelly C, Hardy R, Harris D, Jackman H, Jones R, Luan A,  McAndrew D, McGauley P, Pearce J, Scotney G, Yeow ML. Application of mid-infrared spectroscopy to the development and transfer of a manufacturing process for an active pharmaceutical ingredient. Appl Spectrosc. 2012 May;66(5):574-9. doi: 10.1366/11-06380. PubMed PMID: 22524963.
 
3: Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK. Proc Natl Acad Sci U S A. 2011 May 3;108(18):7535-40. doi: 10.1073/pnas.1019559108. Epub 2011 Apr 18. PubMed PMID: 21502504; PubMed Central  PMCID: PMC3088626.